Medice

Privately held: no public share price · Germany

Assets

(1 total)
1Total Assets
1Approved
0Phase 3 / Filed
0Phase 1–2 / Early
1Diseases
Showing 1 of 1 assets
Target & Modality
Vadadustat(Vafseo)
Approved
HIF prolyl hydroxylase (HIF-PH1/2/3)Small molecule
Chronic Kidney Disease

Upcoming events

No upcoming trial completions or earnings dates on record for this company's assets.

Regulatory and conference events

(2)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

5 November 2026Topline resultVadadustatVOCAL meets its non-inferiority primary endpoint
Akebia Therapeutics · Source ↗
June 2026Topline resultVadadustatVOICE interim analysis met the predefined stopping criteria (non-inferiority and superiority on the primary composite endpoint)

Financial reports

No financial reports recorded.